Sign in to view content

Evaluation of 8 mg Intravitreal Aflibercept Injection for Neovascular Age-Related Macular Degeneration: Results from the Phase 2 CANDELA Study

W. Lloyd Clark, MD, FASRS

Video
Published 2022

Related

Efficacy and Safety of Multiwavelength Photobiomodulation in Dry Age-Related Macular Degeneration Using the LumiThera Valeda System (LIGHTSITE III Interim Analysis)
Richard B. Rosen, MD, DSc(Hon), FACS, FASRS, FARVO
Updates from the Field
2022
Aflibercept Monotherapy vs Initial Bevacizumab Followed by Aflibercept if Needed for Treatment of Center-Involved Diabetic Macular Edema
Chirag D. Jhaveri, MD, FASRS
Updates from the Field
2022
Protocol T Extension Results
John A. Wells, MD, FACS
Updates from the Field
2019

Category: wet AMD

See more